tiprankstipranks
Advertisement
Advertisement

VOR Stock Latest News

Vor Biopharma: Buy Rating Reiterated on Strong Telitacicept Validation and Autoimmune Growth Runway; $31 Price Target Unchanged
RatingsVor Biopharma: Buy Rating Reiterated on Strong Telitacicept Validation and Autoimmune Growth Runway; $31 Price Target Unchanged
14d ago
VOR
Vor Bio price target raised to $18 from $15 at Wedbush
PremiumThe Fly
Vor Bio price target raised to $18 from $15 at Wedbush
17d ago
VOR
Vor Biopharma Advances Phase 3 Telitacicept Trial in Myasthenia Gravis, Keeping Investor Focus High
PremiumCompany Announcements
Vor Biopharma Advances Phase 3 Telitacicept Trial in Myasthenia Gravis, Keeping Investor Focus High
24d ago
VOR
Vor Bio files to sell 5.34M shares of common stock for holders
PremiumThe Fly
Vor Bio files to sell 5.34M shares of common stock for holders
1M ago
VOR
Clene, Lovesac, HDFC Bank, State Street, Vor Shock
PremiumWeekend Updates
Clene, Lovesac, HDFC Bank, State Street, Vor Shock
1M ago
HDB
STT
Bj’s, Atlas, Academy, Vor, Global-e: Insider Shakeup
PremiumWeekend UpdatesBj’s, Atlas, Academy, Vor, Global-e: Insider Shakeup
1M ago
BJ
ASO
Vor Bio price target lowered to $31 from $32 at H.C. Wainwright
Premium
The Fly
Vor Bio price target lowered to $31 from $32 at H.C. Wainwright
2M ago
VOR
Elbit, Vor, Global-e, Sweetgreen, Immunovant: Insider Shake-Up
Premium
Weekend Updates
Elbit, Vor, Global-e, Sweetgreen, Immunovant: Insider Shake-Up
2M ago
SG
VOR
Vor Bio price target raised to $15 from $9 at Wedbush
PremiumThe Fly
Vor Bio price target raised to $15 from $9 at Wedbush
2M ago
VOR
Vor Bio price target lowered to $40 from $55 at Stifel
PremiumThe Fly
Vor Bio price target lowered to $40 from $55 at Stifel
2M ago
VOR
Vor Bio price target lowered to $40 from $55 at Stifel
PremiumThe Fly
Vor Bio price target lowered to $40 from $55 at Stifel
2M ago
VOR
Vor Biopharma: Solid Clinical Execution and Strengthened Balance Sheet Support Buy Rating and Long-Term Growth Outlook
PremiumRatings
Vor Biopharma: Solid Clinical Execution and Strengthened Balance Sheet Support Buy Rating and Long-Term Growth Outlook
2M ago
VOR
Vor Bio doses first patient in UPSTREAM SjD study
PremiumThe FlyVor Bio doses first patient in UPSTREAM SjD study
2M ago
VOR
Vor Bio initiated with a Buy at Jefferies
Premium
The Fly
Vor Bio initiated with a Buy at Jefferies
2M ago
VOR
Vor Biopharma: Strategic Autoimmune Pivot and Telitacicept’s >$2B gMG/SjD Opportunity Underpins Buy Rating
Premium
Ratings
Vor Biopharma: Strategic Autoimmune Pivot and Telitacicept’s >$2B gMG/SjD Opportunity Underpins Buy Rating
2M ago
VOR
Vor Biopharma Announces $75 Million Private Placement Financing
PremiumCompany Announcements
Vor Biopharma Announces $75 Million Private Placement Financing
2M ago
8K
VOR
Vor Bio to sell 5.338M shares at $14.05 in private placement
PremiumThe Fly
Vor Bio to sell 5.338M shares at $14.05 in private placement
2M ago
VOR
Vor Bio initiated with an Overweight at Wells Fargo
PremiumThe Fly
Vor Bio initiated with an Overweight at Wells Fargo
2M ago
VOR
VOR Earnings this Week: How Will it Perform?
PremiumPre-Earnings
VOR Earnings this Week: How Will it Perform?
3M ago
VOR
Galapagos CHRO Annelies Missotten to step down, Tania Philipp to succeed
PremiumThe FlyGalapagos CHRO Annelies Missotten to step down, Tania Philipp to succeed
3M ago
VOR
GLPG
Vor Bio files to sell 13.88M shares of common stock for holders
Premium
The Fly
Vor Bio files to sell 13.88M shares of common stock for holders
4M ago
VOR
Vor Biopharma to Highlight Telitacicept at JPM Conference
Premium
Company Announcements
Vor Biopharma to Highlight Telitacicept at JPM Conference
5M ago
8K
VOR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >